133 related articles for article (PubMed ID: 32944636)
1. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye.
Msaouel P; Walker CL; Genovese G; Tannir NM
Mol Cell Oncol; 2020; 7(5):1777060. PubMed ID: 32944636
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
Msaouel P; Malouf GG; Su X; Yao H; Tripathi DN; Soeung M; Gao J; Rao P; Coarfa C; Creighton CJ; Bertocchio JP; Kunnimalaiyaan S; Multani AS; Blando J; He R; Shapiro DD; Perelli L; Srinivasan S; Carbone F; Pilié PG; Karki M; Seervai RNH; Vokshi BH; Lopez-Terrada D; Cheng EH; Tang X; Lu W; Wistuba II; Thompson TC; Davidson I; Giuliani V; Schlacher K; Carugo A; Heffernan TP; Sharma P; Karam JA; Wood CG; Walker CL; Genovese G; Tannir NM
Cancer Cell; 2020 May; 37(5):720-734.e13. PubMed ID: 32359397
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.
Tourigny DS; Zucker M; Kim M; Russo P; Coleman J; Lee CH; Carlo MI; Chen YB; Hakimi AA; Kotecha RR; Reznik E
Front Oncol; 2022; 12():910147. PubMed ID: 35837094
[TBL] [Abstract][Full Text] [Related]
4. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
5. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
Msaouel P; Tannir NM; Walker CL
Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
7. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
[TBL] [Abstract][Full Text] [Related]
8. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Unclassified Renal Cell Carcinoma With Medullary Phenotype and
Valeri M; Cieri M; Elefante GM; De Carlo C; Rudini N; Lughezzani G; Buffi NM; Terracciano LM; Colombo P
Front Med (Lausanne); 2022; 9():835599. PubMed ID: 35198580
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M; Perelli L; Chen Z; Dondossola E; Ho IL; Carbone F; Zhang L; Khan H; Le CN; Zhu C; Peoples MD; Feng N; Jiang S; Zacharias NM; Minelli R; Shapiro DD; Deem AK; Gao S; Cheng EH; Lucchetti D; Walker CL; Carugo A; Giuliani V; Heffernan TP; Viale A; Tannir NM; Draetta GF; Msaouel P; Genovese G
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2209639120. PubMed ID: 37186844
[TBL] [Abstract][Full Text] [Related]
11. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies.
Shapiro DD; Soeung M; Perelli L; Dondossola E; Surasi DS; Tripathi DN; Bertocchio JP; Carbone F; Starbuck MW; Van Alstine ML; Rao P; Katz MHG; Parker NH; Shah AY; Carugo A; Heffernan TP; Schadler KL; Logothetis C; Walker CL; Wood CG; Karam JA; Draetta GF; Tannir NM; Genovese G; Msaouel P
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885132
[TBL] [Abstract][Full Text] [Related]
12. A case of renal cell carcinoma unclassified with medullary phenotype without detectable gene deletion.
Tsuzuki S; Kataoka TR; Ito H; Ueshima C; Asai S; Yokoo H; Haga H
Pathol Int; 2019 Dec; 69(12):710-714. PubMed ID: 31617267
[TBL] [Abstract][Full Text] [Related]
13. Renal medullary carcinoma in a young mixed-race man in Japan.
Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
[TBL] [Abstract][Full Text] [Related]
14. Renal medullary carcinomas depend upon
Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
Elife; 2019 Mar; 8():. PubMed ID: 30860482
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
Lai JZ; Lai HH; Cao D
Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
[TBL] [Abstract][Full Text] [Related]
16. Unusual Presentation of Renal Medullary Carcinoma With Undiagnosed Sickle Cell Trait.
Basher F; Dutcher G; England JS; Lopes G
Cureus; 2020 Sep; 12(9):e10731. PubMed ID: 33145136
[TBL] [Abstract][Full Text] [Related]
17. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
18. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
19. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
[TBL] [Abstract][Full Text] [Related]
20. Renal medullary carcinoma in a white adolescent with sickle cell trait.
Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]